COVID Treatment

Study investigators observed no significant differences in oxygen supplementation, hospitalization, or COVID-19 related death between initiators and non-initiators, though they cautioned more research was needed.

Investigators found that age and the presence of RNAemia in blood were predictors of mortality in patients with severe COVID-19.

Rates of hospitalizations and mortality from COVID-19 were more than 4 times lower in 2022 compared to 2021, as the virus become less severe with new mutations, a recent study found.

The research narrows the most at-risk populations and how to mitigate the impacts on adults with ADRD.

Not only is a combination of in-office visits and telemedicine an effective model of prenatal care, but it can be an alternative to those who face access barriers.

Many living in lower-income rural populations face significant unmet social needs that can bar access to important mental health services.

The findings could help in future vaccine prioritization strategies and therapeutic allocation policies for other pandemic.

The approval makes remdesivir the first and only approved antiviral treatment for patients across all stages of renal disease.

A potential new drug therapy found from blood proteins could improve outcomes for individuals diagnosed with long COVID.

Using artificial intelligence to sort and respond to patient queries could streamline processes and alleviate provider burnout.

Pre-exposure prophylaxis of neutralizing SARS-CoV-2 monoclonal antibodies may be preventative against SARS-CoV-2 transmission, decreasing frequency of new infections and number of hospitalized patients who need antiviral therapies, thus lowering costs.

The study also found significant evidence of outcomes disparities between minority populations and White populations.

In-person visits to receive oral therapy, outpatient infusions, and inpatient infusion for the treatment of hematologic neoplasms declined in the early months of the COVID-19 pandemic, while telemedicine use increased slightly in the same period but remained low overall.

There may be more than 200 symptoms associated with long COVID-19.

Investigators found thinner ventricular walls, disorganized and ruptured myocardial fiber, mild inflammatory infiltration, and mild epicardia or interstitial fibrosis in the hearts of mice infected with COVID-19.

Pharmacogenomic testing in combination with therapeutic drug monitoring can be a cost effective and efficient way to advance psychiatric drug therapy.

Decentralization has already been shown to streamline clinical trials, but it also has the potential to improve the broader health care ecosystem.

With so many radical developments in medicine and technology unfolding at once, the role and potential of the pharmacy as we know it is evolving at breakneck speed.

This marks the fourth drug, and first oral antiviral pill, approved by the FDA to treat adults with mild-to-moderate COVID-19.

The risk of long COVID-19 in females in the least deprived areas was comparable to the risk of males in the most deprived areas.

Federal legislation addresses variety of issues and seeks to build on gains made under the Affordable Care Act.

Study evaluates the effect of long-acting monoclonal antibodies tixagevimab and cilgavimab treating COVID-19 symptoms and viral shedding.

Study shows that the nervous system of individuals experiencing post-COVID-19 fatigue is underactive in 3 key areas.

Neutralizing monoclonal antibody therapies found to improve outcomes for unvaccinated and nonhospital patients at high risk of poor outcome for SARS-CoV-2.

Study shows intramuscular injection may improve treatment success by increasing the speed of drug absorption.

The SUNRISE-3 trial is investigating its use in high-risk patients regardless of COVID-19 vaccination status.

All-cause inpatient mortality or discharge to hospice was lower for patients who received dexamethasone within 48 hours of either admission or escalation in oxygen support.

Emerging evidence suggests that the risk of maternal mortality was more than 10-times greater among those with COVID-19 infection.

Patients administered anakinra did not meet a study’s primary endpoint of proportion of patients who did not need mechanical ventilation 15 days after starting treatment for severe COVID-19 pneumonia.

The role of monoclonal antibodies in minimizing COVID-19–related complications remains important to assess.